For patients with Her2/neu-positive breast cancer, trastuzumab (herceptin) was recommended as first line treatment for a significant improvement in DFS and OS of patients with early or late stage breast cancers.17,19 In our study, a high rate of trastuzumab-refusal may underestimate the efficacy of adjuvant chemotherapy. The gene discussed is ERBB2; the disease is breast cancer.